Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Erectile dysfunction drug approved to treat BPH symptoms.

[No authors listed]

Mayo Clin Health Lett. 2012 Apr;30(4):4. No abstract available.

PMID:
22649816
2.

Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.

Cantrell MA, Baye J, Vouri SM.

Pharmacotherapy. 2013 Jun;33(6):639-49. doi: 10.1002/phar.1243. Epub 2013 Mar 25. Review.

PMID:
23529917
3.

Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, Park JK.

BJU Int. 2011 Jun;107(12):1943-7. doi: 10.1111/j.1464-410X.2010.09759.x. Epub 2010 Nov 5.

4.

Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.

Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L.

Eur Urol. 2009 Oct;56(4):727-35. doi: 10.1016/j.eururo.2009.04.033. Epub 2009 Apr 22. Erratum in: Eur Urol. 2011 Jun;59(6):1082.

PMID:
19409693
5.

Tadalafil for benign prostatic hyperplasia.

[No authors listed]

Drug Ther Bull. 2013 Aug;51(8):93-6. doi: 10.1136/dtb.2013.8.0199.

PMID:
23949822
6.

Monotherapy for comorbid erectile dysfunction and lower urinary tract symptoms: phosphodiesterase inhibitor or α-adrenoceptor antagonist?

Wyllie MG.

BJU Int. 2012 Apr;109(7):965-6. doi: 10.1111/j.1464-410X.2012.10984.x. Epub 2012 Feb 28. No abstract available.

7.

Editorial comment on: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.

Volpe A.

Eur Urol. 2009 Oct;56(4):735-6. doi: 10.1016/j.eururo.2009.04.034. Epub 2009 Apr 22. No abstract available.

PMID:
19409694
8.

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.

Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L.

Urology. 2010 Jun;75(6):1452-8. doi: 10.1016/j.urology.2009.09.093. Epub 2010 Feb 16.

PMID:
20163842
9.

Coming attractions! New medications on the horizon for erectile dysfunction.

Gaines KK.

Urol Nurs. 2003 Aug;23(4):303-4. No abstract available.

PMID:
14552078
10.

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.

Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L.

BJU Int. 2010 Feb;105(4):502-7. doi: 10.1111/j.1464-410X.2009.08822.x. Epub 2009 Sep 3.

11.

Editorial comment.

de la Rosette JJ.

Urology. 2010 Jun;75(6):1458. doi: 10.1016/j.urology.2009.10.071. No abstract available.

PMID:
20513508
13.
14.

[Should we prescribe phosphodiesterase inhibitors for the treatment of symptomatic benign prostatic hyperplasia].

Caviezel A, Iselin CE.

Rev Med Suisse. 2011 Dec 7;7(320):2394-7. French.

PMID:
22232868
15.

Erectile dysfunction: the Viagra revolution.

[No authors listed]

Harv Mens Health Watch. 2005 Apr;9(9):1-6. No abstract available.

PMID:
18217258
16.

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.

Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.

J Urol. 2008 Oct;180(4):1228-34. doi: 10.1016/j.juro.2008.06.079. Epub 2008 Aug 22.

PMID:
18722631
17.
18.

Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men.

Mazur DJ, Helfand BT, McVary KT.

Urol Clin North Am. 2012 Feb;39(1):77-88. doi: 10.1016/j.ucl.2011.09.005. Epub 2011 Oct 13. Review.

PMID:
22118347
19.

Beyond Viagra. What are your options?

[No authors listed]

Mayo Clin Health Lett. 2006 Jan;24(1):7. No abstract available.

PMID:
16468157
20.

Benign prostatic hyperplasia and erectile dysfunction--is there a link?

Vale J.

Curr Med Res Opin. 2000;16 Suppl 1:s63-7. Review.

PMID:
11329825

Supplemental Content

Support Center